… Concurrent detection with high sensitive methods of classical EGFR mutation and the T790M
mutation cannot represent an exclusion criterion for front-line erlotinib therapy. Erlotinib in …

… of 1st line erlotinib in patients with advanced NSCLC. Methods: Chemotherapy-naïve, stage
IIIB/IV, PS 0–2, NSCLC patients have been enrolled to receive erlotinib … received erlotinib …

… in which we aimed to compare erlotinib with platinum-based chemotherapy as first-line
treatment for patients with advanced NSCLC. Our trial is the first randomised trial targeting a non-…

… (PFS) benefit for first-line erlotinib versus chemotherapy in … erlotinib was also reported
in the Chinese, phase III, first-line OPTIMAL study [10]. Additionally, the single-arm, first-line…

… of 11 months with erlotinib, on the basis of data from the Spanish Lung Cancer Group (SLCG), …
activating mutations should receive erlotinib as first-line therapy on the basis of this study. …

… sequential combination of chemotherapy with erlotinib, followed by erlotinib maintenance
therapy. In conclusion, first-line sequential administration of erlotinib with chemotherapy has …

… In contrast, some patient's performance status improved noticeably and rapidly after
erlotinib therapy. Some still argue that our study could not support the use of first-line erlotinib …

… Background: In phase II studies, erlotinib has shown single agent activity in a number of tumor
… (EGFR) inhibitor erlotinib (Tarceva) prolongs survival in NSCLC patients after 1 st or 2 nd …

… -mutant tumors to erlotinib or erlotinib plus carboplatin and paclitaxel as first-line treatment.
PFS was similar in both groups: 5.0 months for erlotinib versus 6.6 months for erlotinib plus …

… It remains unclear whether first-line erlotinib produces similar … first phase III, randomised,
open-label study to compare first-… in the erlotinib arm were still receiving first-line erlotinib at OS …